Reperfusion, procedural, and clinical outcomes in the balloon guide catheter group compared with the non-balloon guide catheter group in anterior circulation cases
| BGC (n=279) (n (%)) | Non-BGC (n=257) (n (%)) | P Value | |
| Reperfusion outcome | |||
| Reperfusion mTICI ≥2b | 235 (84.2) | 194 (75.5) | 0.01 |
| Reperfusion mTICI ≥2a | 266 (95.3) | 230 (89.5) | 0.01 |
| Reperfusion mTICI 3 | 127 (45.5) | 106 (41.3) | 0.41 |
| First pass effect* | 68 (25.3) | 49 (19.8) | 0.14 |
| M1 reperfusion mTICI ≥2b | 147 (83.5) | 130 (77.8) | 0.18 |
| M2 reperfusion mTICI ≥2b | 38 (80.9) | 23 (65.7) | 0.12 |
| Other technical outcomes | |||
| Reperfusion time (min) (median (IQR)) | 56(35-93) | 61.5 (38.3–98.8) | 0.51 |
| No of passes (mean (SD)) | 2.0 (1.2) | 2.0 (1.1) | 0.40 |
| No of passes (median (IQR)) | 2 (1–2.3) | 2 (1–3) | 0.40 |
| Rescue therapy | 53 (19.0) | 61 (23.7) | 0.17 |
| Clinical outcomes | |||
| Primary: †Good clinical outcome mRS ≤2 (90 day) | 148/262 (56.5) | 92/228 (40.4) | 0.0004 |
| Secondary: discharge NIHSS (mean (SD)) | 8.3 (8.4) | 12.8 (11.8) | <0.0001 |
| Discharge NIHSS (median (IQR)) | 6 (2–13) | 10(3-18) | <0.0001 |
| Safety | |||
| Symptomatic hemorrhage | 15 (5.4) | 24 (9.3) | 0.09 |
| Mortality* | 33 (13.4) | 47 (23.0) | 0.008 |
*90 day outcomes were available in 490/536 (91.4%) patients.
†First pass effect is defined as achieving mTICI 3 with the first pass of the Trevo device.
BGC, balloon guide catheter; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; tPA tissue plasminogen activator.